



## Making an Initial Authorisation Request

An Initial Authorisation Request will need to be submitted if the patient is required to have Immunoglobulin (Ig) but is not an authorised patient in BloodSTAR or their authorisation has expired.

## Submitting a New Initial Authorisation Request

1. There are two ways to start a New Initial Authorisation Request.

**Option A:** From your home page as a Medical Officer, click the **Authorisation Requests** tab at the top of the page and click **New Initial Authorisation Request**.

<b>BLOOD</b> STAR	Home	Patients 👻	Authorisation Requests 🗸	Treatment +	BloodSTAR Messages
			New Initial Authorisation R	lequest	
Added 04-Mar-2024			My Authorisation Requests	5	

**Option B**: Click the **+ New Initial Authorisation Request** large green button on the homepage.

My Authorised F	atients	Pending Reviews	My Requests						
Show patier	Show patients where I am + New Initial Authorisation Request								
Treating M	Treating Medical Specialist								
🗹 Requesting	Medical (	Officer							
Diagnosing	Medical (	Officer							
Verified Dia	agnosis M	edical Officer							
Patient	Patient Date of Birth Treating Facility Patient ID Medical Condition End Date Authorisation								
	No results found								
H 4 1	Image: Strategy of the state strategy of the strategy of								

2. A Find Patient for Initial Authorisation Request window will appear, as shown below.

Enter the full name and date of birth of the patient and click **Find Patient**. If there is an exact match, the patient will appear for you to select and continue with a patient already in BloodSTAR; **a partial match will not return results**. If there is no match, select **Continue** to create patient and progress with the authorisation request.

Given Name			
Date of Birth	t .		
Patient ID		0	
іні		0	
Find Pa	atient		





3. Enter in your patient's consent status, select whether the consent granted was verbal or written, who granted the consent and the date it was obtained. You can nominate if the consent status is recorded in the medical record and (optionally) upload a scanned copy of any consent you have received in writing.



Privacy Consent	
Consent Documents	Patient Privacy Consent Form More Information - Privacy Statement and Notice
Consent Status *	<b>•</b>
Date *	
Recorded in Medical Record	
Attach Copy	Select files
	Save Cancel









4. Once your patient's basic details have been entered and consent obtained, you will be taken to Step 1 of the **Initial Authorisation Request**. There are three functions you can perform on this page:

Step 1	
Patient Details	Q Change Patient
Patient	
Date of Birth	
Sex	11 P
State	
Postcode	
	Add
Privacy Consent	Consent Obtained
	Edit Patient Details
Previous Treatments	
+ Add Previous Treatment	
Treatment Type Product	Date (mm/yyyy) Response
Treating Medical Specialist *	B Lam the Treating Medical Specialist Q Select Treating Medical Specialist
No treating medical specialist selecte	d.
Urgency	
Urgency *	Standard
orgency	
	Save Save and Continue

- A. If relevant, enter any previous treatments for the patient by clicking + Add Previous Treatment.
- B. Add the Treating Medical Specialist details to the form. If you are the Treating Medical Specialist, click on, I am the Treating Medical Specialist. If you are the Requesting Medical Officer select
   Change Treating Medical Specialist to nominate a prescribing specialist.
- C. Set the urgency of the authorisation to one of the following:
  - **Standard:** Request will be assessed within 2 business days.
  - **Serious:** Request will be assessed within 1 business day.
  - **Emergency:** Request will be assessed in 2 hours and a follow up call will be required.

**Note:** Authorisations that have a status of **Emergency** *must be accompanied by a call to* Lifeblood Authorisers on 1300 70 77 55 after the authorisation has been submitted. Once all necessary details have been entered, click *Save and Continue*.

support@blood.gov.au







5. In Step 2, the **Treating and Administering Facility** will be auto populated as the facility where the nominated Treating Medical Specialist is registered. If your patient will physically receive treatment at another facility, select that site from the **Administering Facility** drop-down menu and, if not auto populated, select a **Dispensing Facility**.

Step 2	
Treatment Arrangements	
Treating Facility *	
Dispensing Facility *	•

The facility types are as follows:

- **Treating Facility:** the facility at which a specific patient's treatment will be managed (diagnosed, prescribed, and reviewed). This may be the same location as the Ig infusion is administered.
- Administering Facility: the facility where the patient goes regularly to have their Ig infusions administered. This may be the same location that the patient sees their Treating Medical Specialist.
- **Dispensing Facility:** the facility from which it is anticipated that product will be normally dispensed for a specific authorised patient.
- 6. Begin typing the diagnosis into the **Find Condition** field. All the possible diagnosis options will populate to be selected. Once a medical condition has been selected, the page will continue to populate further required details under **Qualifying Criteria** and **Supporting Evidence**. To assist in the assessment of your authorisation request, please ensure you enter as much information as you have available. When completed, click **Save** and **Continue**.

I	Diagnosis and Criteria	
	Q Find Condition	
	Guil	¢
	Guillain-Barré Syndrome including variants (GBS)	Î
	Guillain–Barré Syndrome including variants (GBS)	

**Note:** When creating an initial authorisation, if the selected medical condition is not supported by the criteria, an error message will be displayed, and the request will not be able to be continued. The error message is as follows



4





	Q Find another condition
Medical Condition *	Crohn's disease
	C <sup>*</sup> <u>View Criteria</u>
	Real Section 2015 Is the selected medical condition. Please refer to the Criteria for the clinical use of immunoglobulin in Australia for further information or contact Lifeblood on 1300 707 755. For conditions not supported within the Criteria patients may obtain Ig via <u>Direct Order</u> arrangements or directly from relevant suppliers.

7. In Step 3, enter the Patient Weight. If you are calculating dosage by Ideal Body Weight, tick the corresponding box User Ideal Body Weight Adjusted Dosing and a Height field will appear. This will then alter the weight value according to Ideal Weight values and change the requested dosage accordingly. Otherwise, just enter the patient's weight.

Step 3		
Patient Weight *	kg	Suse Ideal Body Weight Adjusted Dosing 🕢
Patient Height *	Last Recorded Weight: 54.90 kg	Ideal body weight adjusted dosing is only recommended in patients who:
Is Patient Pregnant	nt □ ✓ are aged over 18 years	
		✓ are greater than 152cm in height
		✓ are not pregnant
		$\checkmark$ weigh more than the Dose Determining Weight (mandatory)

Note: Patients previous weight will be shown if they had a previous authorisation request.



support@blood.gov.au





Select one or more doses that are required where clinically appropriate such as maintenance or loading dose, from the available options. The options available are determined by the diagnosis selected.

Patient Weight * Patient Height ¢ cm	<ul> <li>□ Use Ideal Body Weight Adjusted Dosing ●</li> <li>Ideal body weight adjusted dosing is recommended in patients who:         <ul> <li>are aged over 18 years</li> <li>are greater than 152cm in height</li> <li>are not pregnant</li> <li>weigh more than the Dose Determining Weight (mandatory)</li> </ul> </li> </ul>
ease note that more than one dose type can be selected where available and clini ntravenous Doses	cally appropriate.
Description: One loading dose of 2 g/kg in 2 to 5 divided doses in the first month	n of therapy (in addition to the maintenance dose) is permitted.
Description: One loading dose of 2 g/kg in 2 to 5 divided doses in the first month Maintenance Dose (IVIg)	n of therapy (in addition to the maintenance dose) is permitted.
Description: One loading dose of 2 g/kg in 2 to 5 divided doses in the first month Maintenance Dose (IVIg) Description: 0.4–1g/kg, is permitted every 2 to 6 weeks. The amount per dose sh may be given in any 4 week period. This might be by smaller doses more frequen	n of therapy (in addition to the maintenance dose) is permitted. Iould be titrated to the individual's response, and may be reduced while weaning. A maximum dose of 2g/kg (t)y than fortnightly.
Description: One loading dose of 2 g/kg in 2 to 5 divided doses in the first month Maintenance Dose (IVIg) Description: 0.4–1g/kg, is permitted every 2 to 6 weeks. The amount per dose sh may be given in any 4 week period. This might be by smaller doses more frequen Supplementary Dose (IVIg)	h of therapy (in addition to the maintenance dose) is permitted. iould be titrated to the individual's response, and may be reduced while weaning. A maximum dose of 2g/kg itly than fortnightly.

9. The **Product and Dose/Kg** will be prepopulated and is determined by the entered diagnosis and your state. Enter the details of the treatment, including **Frequency**, **Date Required** and any comments.

Infusion Method *	Intravenous 🔻	
Product	The allocated Intravenous product for this condition is <b>PRIVIGEN AU.</b> Available sizes: <b>5.00 g</b> , <b>10.00 g and 20.00 g</b> The allocated product is based on the most recently approved product for the	patient.
Request a different product		
Dose / Kg *	0.40 🗘 g Total Dose *	40.00 g The total dose will be rounded to 40 g due to available product sizes.
Frequency * Date Required *	Every 2 Course(s) 12-Mar-2024	07-May-2024
Dose will be administered as a divided dose Comments		
	This dose is also available as subcutaneous immunoglobulin.	

If you need to select a different product, proceed with this step. Otherwise, skip to step 11.
 Tick the box marked **Request a different product**. A mandatory field will appear for you to select an alternate product from the drop-down list and a **valid clinical reason** must be provided.

A	You must provide a valid clinical reason for requesting a different product that BloodSTAR.	n what is allocated in
	Lifeblood Authorisers closely review requests to change an allocated product. If clii provided, the request for a different product may not be approved.	nical justification is not
	Preferred Product: *	
	Reason: *	
13 000 BLOOD (1300 025	663) Support@blood.gov.au	102 6151 5210





11. If the dose is to be administered as a divided dose, click on the **Dose will be administered as a divided dose** checkbox. The option to specify the **Number of divisions** will appear as well as the option to **Specify your own divisions**. If you do not select the **Specify my own divisions** option, BloodSTAR will automatically divide the dose as equally as is possible with the available vial sizes of the specified product. If you select **Specify my own divisions** of the total dose.

Dose will be administered as a divided dose				
Number of divisions *	4	(10.00 g,	10.0	0 g, '
Specify my own divisions				
Divisions *	Division	Quantity		
	1*	10.00	*	g
	2 *	10.00	*	g
	3*	10.00	*	g
	4 *	10.00	*	g

Please note: Treatment duration and amount per kilogram is calculated automatically off the weight Ø entered for the patient. If you need to prescribe more than the recommended maximum of product per kilogram, enter this under Dose/Kg. If the Dose/Kg is higher than the recommended amount under the criteria you must enter a reason. When all details are completed, click Save and Continue.

12. Confirm all details and check the box **Accepting Terms and Conditions**. Click **Submit** to complete the request.

Step 4 - Submission						
To assist with the assessment of this request please enter a contact name and number(s) for an authoriser to contact you if needed.						
Contact Name *						
Contact Number(s) *						
This request is ready for submission. Please review the request details and click 'Submit' to submit this request						
I acknowledge the governance and management arrangements for the appropriate supply and use of immunoglobulin products, funded under the national blood arrangements, and the provision of information required to support authorisation. To the best of my knowledge, the information provided in this form is true and correct.						
I have explained to the patient (or parent/carer/guardian) and I believe that they are aware of and understand:						
<ul> <li>the risks and benefits of treatment with immunoglobulin products and alternative treatments (where these exist),</li> <li>the national access conditions and governing requirements for the appropriate supply and use of immunoglobulin products</li> <li>under the national blood arrangements, including that immunoglobulin products may need to change from time to time</li> <li>(for patients requiring ongoing treatment only) the nature of ongoing monitoring and review and that access to product will cease if response to treatment does not demonstrate clinical benefit.</li> </ul>						
Previous Step	Submit					